REFERENCES
- Surawicz T. S., McCarthy B. J., Kupelian V., Jukich P. J., Bruner J. M., Davis F. G. Descriptive epidemiology of primary brain and CNS tumors: results from the CentralBrain Tumor Registry of the United States, 1990–1994. Neuro-Oncol. 1999; 1(1)14–25
- Packer R. J., Cogen P., Vezina G., Rorke L. B. Medulloblastoma: clinical and biologic aspects. Neuro-Oncol. 1999; 1(3)232–250
- Giordana M. T., Schiffer P., Schiffer D. Prognostic factors in medulloblastoma. Childs Nerv Syst. 1998; 14(6)256–262
- Chang C. H., Housepian E. M., Herbert C. J. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969; 93(6)1351–1359
- Merchant T. E., Wang M. H., Haida T., Lindsley K. L., Finlay J., et al. Medulloblastoma: long-term results for patients treated with definitive radiation therapy during the computed tomography era. Int. J Radiat. Oncol. Biol. Phys. 1996; 36(1)29–35
- Gajjar A., Kuhl J., Epelman S., Bailey C., Allen J. Chemotherapy of medulloblastoma. Childs Nerv. Syst. 1999; 15(10)554–562
- Kortmann R. D., Kuhl J., Timmermann B., Mittler U., Urban C., et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT 1991. Int. J. Radiat. Oncol. Biol. Phys. 2000; 46(2)269–279
- Newton H. B. Review of the molecular genetics and chemotherapeutic treatment of adult nd paediatric medulloblastoma. Expert. Opin. Investig. Drugs. 2001; 10(12)2089–2104
- Zeltzer P. M., Boyett J. M., Finlay J. L., Albright A. L., Rorke L. B., et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J. Clin. Oncol. 1999; 17(3)832–845
- Chintagumpala M., Berg S., Blaney S. M. Treatment controversies in medulloblastoma. Curr. Opin. Oncol. 2001; 13(3)154–159
- Chinot O. New place of the chemotherapy in gliomas. Bull. Cancer. 2005; 92(4)343–54
- Yung W. K. Temozolomide in malignant gliomas. Semin. Oncol. 2000; 27: 27–34, (3 Suppl. 6)
- Newlands E. S., Stevens M. F., Wedge S. R., Wheelhouse R. T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 1997; 23(1)35–61
- Yung W. K., Albright R. E., Olson J., Fredericks R., Fink K., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer. 2000; 83(5)588–93
- Stupp R., Mason W. P., van den Bent M. J., Weller M., Fisher B., et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005; 352(10)987–996
- O'Reilly S. M., Newlands E. S., Glaser M. G., Brampton M., Rice-Edwards J. M., et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer. 1993; 29A(7)940–942
- Hongeng S., Visudtibhan A., Dhanachai M., Laothamatus J., Chiamchanya S. Treatment of leptomeningeal relapse of medulloblastoma with temozolomide. J. Pediatr. Hematol. Oncol. 2002; 24(7)591–593
- Cefalo G., Ruggiero A., Abate M. E., Riccardi R. High response rte to temozolomide in heavily pretreated children and young adults with medulloblastoma. Neuro-Oncol. 2002; 74, (Abstr 4:1)